Toward personalized therapeutic drug monitoring of ustekinumab in Crohn’s disease: influence of previous exposure to biologics
Ustekinumab TLs in patients may differ according to their prior exposure to biologic agents and disease activity. Accordingly, rather than applying a uniform threshold, ustekinumab levels should be interpreted using individualized, patient-specific strategies in clinical practice.
Authors
- Yiyoung Kwon (ORCID: https://orcid.org/0000-0001-5600-2070)
- Tae Jong Jeong (ORCID: https://orcid.org/0000-0002-6221-4149)
- Yon Ho Choe (ORCID: https://orcid.org/0000-0003-1525-7688)
- Yoon Zi Kim (ORCID: https://orcid.org/0000-0002-1568-3364)
- Eun Sil Kim (ORCID: https://orcid.org/0000-0003-2012-9867)
- Seon Young Kim (ORCID: https://orcid.org/0000-0001-6433-0242)
- Hansol Kim (ORCID: https://orcid.org/0000-0003-4444-5522)
- Mi Jin Kim (ORCID: https://orcid.org/0000-0002-4505-4083)
Institutions
- Samsung Medical Center (KR)
- Kyung Hee University (KR)
- Kangbuk Samsung Hospital (KR)
- Pusan National University Yangsan Hospital (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1177/17562848251393074
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00